| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 50,899 | 39,510 | ||
| Prepaid expenses and other current assets | 3,665 | 3,456 | ||
| Total current assets | 54,564 | 42,966 | ||
| Property and equipment, gross | 5,007 | - | ||
| Less accumulated depreciation and amortization | 3,905 | - | ||
| Property and equipment, net | 1,102 | 1,331 | ||
| Operating lease right-of-use assets | 1,236 | 1,560 | ||
| Restricted cash | 417 | 417 | ||
| Other non-current assets | 150 | 192 | ||
| Total assets | 57,469 | 46,466 | ||
| Accounts payable | 9,166 | 8,034 | ||
| Current portion of operating lease liabilities | 1,703 | 1,954 | ||
| Accrued expenses and other current liabilities | 10,172 | 10,512 | ||
| Total current liabilities | 21,041 | 20,500 | ||
| Warrant liability | 22,593 | - | ||
| Other non-current liabilities | 2,264 | 2,264 | ||
| Non-current portion of operating lease liabilities | - | 201 | ||
| Total liabilities | 45,898 | 22,965 | ||
| Common stock 0.0001 par value 492,000,000 shares authorized at september 30, 2025 and december 31, 2024 27,984,039 and 15,022,122 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 3 | 2 | ||
| Additional paid-in capital | 319,137 | 312,332 | ||
| Accumulated deficit | -307,569 | -288,833 | ||
| Total stockholders equity | 11,571 | 23,501 | ||
| Total liabilities and stockholders equity | 57,469 | 46,466 | ||
Jasper Therapeutics, Inc. (JSPRW)
Jasper Therapeutics, Inc. (JSPRW)